Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
Financial Results:
Caplin Point Laboratories Ltd reported Revenues for Q2FY25 of ₹483.00 Crores up from ₹410.00 Crore year on year, a rise of 17.8%.
Total Expenses for Q2FY25 of ₹335.00 Crores up from ₹285.00 Crores year on year, a rise of 17.54%.
Consolidated Net Profit of ₹131.00 Crores up 12.93% from ₹116.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹17.21, up 13.75% from ₹15.13 in the same quarter of the previous year.